BACKGROUND: Clinical practice guidelines for management of chronic kidney disease (CKD) have been developed within the Kidney Disease Outcomes Quality Initiative (K/DOQI). Adherence patterns may identify focus areas for quality improvement. METHODS: We retrospectively studied contemporary CKD care patterns within a private health system in the United States, and systematically reviewed literature of reported practices internationally. Five hundred and nineteen patients with moderate CKD (estimated GFR 30-59 ml/min) using healthcare benefits in 2002-2005 were identified from administrative insurance records. Thirty-three relevant publications in 2000-2006 describing care in 77,588 CKD patients were reviewed. Baseline demographic traits and provider specialty were considered as correlates of delivered care. Testing consistent with K/DOQI guidelines and prevalence of angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) medication prescriptions were ascertained from billing claims. Care descriptions in the literature sample were based on medical charts, electronic records and/or claims. RESULTS: KDOQI-consistent measurements of parathyroid hormone (7.1 vs. 0.6%, P = 0.0002), phosphorus (38.2 vs. 1.9%, P < 0.0001) and quantified urinary protein (23.8 vs. 9.4%, P = 0.008) were more common among CKD patients with versus without nephrology referral in the administrative data. Nephrology referral correlated with increased likelihood of testing for parathyroid hormone and phosphorus after adjustment for baseline patient factors. Use of ACEi/ARB medications was more common among patients with nephrology contact (50.0 vs. 30.0%; P = 0.008) but appeared largely driven by higher comorbidity burden. The literature review demonstrated similar practice patterns. CONCLUSIONS: Delivery of CKD care may be monitored by administrative data. There is opportunity for improvement in CKD guideline adherence in practice.
BACKGROUND: Clinical practice guidelines for management of chronic kidney disease (CKD) have been developed within the Kidney Disease Outcomes Quality Initiative (K/DOQI). Adherence patterns may identify focus areas for quality improvement. METHODS: We retrospectively studied contemporary CKD care patterns within a private health system in the United States, and systematically reviewed literature of reported practices internationally. Five hundred and nineteen patients with moderate CKD (estimated GFR 30-59 ml/min) using healthcare benefits in 2002-2005 were identified from administrative insurance records. Thirty-three relevant publications in 2000-2006 describing care in 77,588 CKD patients were reviewed. Baseline demographic traits and provider specialty were considered as correlates of delivered care. Testing consistent with K/DOQI guidelines and prevalence of angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) medication prescriptions were ascertained from billing claims. Care descriptions in the literature sample were based on medical charts, electronic records and/or claims. RESULTS: KDOQI-consistent measurements of parathyroid hormone (7.1 vs. 0.6%, P = 0.0002), phosphorus (38.2 vs. 1.9%, P < 0.0001) and quantified urinary protein (23.8 vs. 9.4%, P = 0.008) were more common among CKD patients with versus without nephrology referral in the administrative data. Nephrology referral correlated with increased likelihood of testing for parathyroid hormone and phosphorus after adjustment for baseline patient factors. Use of ACEi/ARB medications was more common among patients with nephrology contact (50.0 vs. 30.0%; P = 0.008) but appeared largely driven by higher comorbidity burden. The literature review demonstrated similar practice patterns. CONCLUSIONS: Delivery of CKD care may be monitored by administrative data. There is opportunity for improvement in CKD guideline adherence in practice.
Authors: Janice P Lea; William M McClellan; Charlene Melcher; Elisa Gladstone; Tom Hostetter Journal: Am J Kidney Dis Date: 2006-01 Impact factor: 8.860
Authors: John B Kostis; Harold J Kim; James Rusnak; Thomas Casale; Allen Kaplan; Jonathan Corren; Elliott Levy Journal: Arch Intern Med Date: 2005-07-25
Authors: George R Bailie; George Eisele; Lei Liu; Erik Roys; Margaret Kiser; Frederick Finkelstein; Robert Wolfe; Friedrich Port; Sally Burrows-Hudson; Rajiv Saran Journal: Nephrol Dial Transplant Date: 2005-03-15 Impact factor: 5.992
Authors: Wolfgang C Winkelmayer; Michael A Fischer; Sebastian Schneeweiss; Philip S Wang; Raisa Levin; Jerry Avorn Journal: Am J Kidney Dis Date: 2005-12 Impact factor: 8.860
Authors: Adrienne S Allen; John P Forman; E John Orav; David W Bates; Bradley M Denker; Thomas D Sequist Journal: J Gen Intern Med Date: 2010-10-05 Impact factor: 5.128
Authors: Krista L Lentine; Huiling Xiao; Gerardo Machnicki; Adrian Gheorghian; Mark A Schnitzler Journal: Clin J Am Soc Nephrol Date: 2010-06-10 Impact factor: 8.237
Authors: Joseph Menzin; Lisa M Lines; Daniel E Weiner; Peter J Neumann; Christine Nichols; Lauren Rodriguez; Irene Agodoa; Tracy Mayne Journal: Pharmacoeconomics Date: 2011-10 Impact factor: 4.981
Authors: Khaled Abdel-Kader; Gary S Fischer; Jie Li; Charity G Moore; Rachel Hess; Mark L Unruh Journal: Am J Kidney Dis Date: 2011-10-07 Impact factor: 8.860
Authors: Robert B Hopkins; Amit X Garg; Adeera Levin; Anita Molzahn; Claudio Rigatto; Joel Singer; George Soltys; Steven Soroka; Patrick S Parfrey; Brendan J Barrett; Ron Goeree Journal: Clin J Am Soc Nephrol Date: 2011-05-26 Impact factor: 8.237
Authors: Samuel A Silver; Chaim M Bell; Glenn M Chertow; Prakesh S Shah; Kaveh Shojania; Ron Wald; Ziv Harel Journal: Clin J Am Soc Nephrol Date: 2017-09-06 Impact factor: 8.237
Authors: Ana C Ricardo; Jason A Roy; Kaixiang Tao; Arnold Alper; Jing Chen; Paul E Drawz; Jeffrey C Fink; Chi-Yuan Hsu; John W Kusek; Akinlolu Ojo; Martin Schreiber; Michael J Fischer Journal: J Gen Intern Med Date: 2015-07-03 Impact factor: 5.128